Sergio Giralt, MD
Hematology & Oncology · New York, NYNPI 1639278880
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 23.1%. Reporting peaked in 2021 at $76,726 and has fallen 70.8% since, to $22,391 in 2025. Among hematology & oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 198 payments — averaging $1621.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$74K
- Pfizer$45K
- CSL Behring$37K
- Incyte Corporation$33K
- Gilead$29K
- Omeros Corporation$23K
- plus $80K from 23 others
Across 36 payments — averaging $177,804 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$6.2M
- National Marrow Donor Program$107K
- Gilead$38K
- Omeros Corporation$23K
- E.r. Squibb & Sons, L.L.C.$5K
- Pfizer$5K
- plus $800 from 1 others
What the payments were for
- Consulting fees$167,59152%
- Speaking & faculty fees$111,73335%
- Grants$1030%
- Travel & lodging$37,31612%
- Food & beverage$4,3181%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 16 | $74,071 |
| Pfizer(2 entities) | 13 | $44,850 |
| CSL Behring | 22 | $36,981 |
| Incyte Corporation | 30 | $33,110 |
| Gilead | 26 | $28,885 |
| Omeros Corporation | 19 | $23,335 |
| Amgen | 17 | $12,094 |
| Gamida Cell Inc. | 1 | $9,120 |
| E.r. Squibb & Sons, L.L.C. | 4 | $7,838 |
| Regeneron | 7 | $7,051 |
| Janssen Global Services, LLC | 7 | $6,313 |
| Daiichi Sankyo Inc. | 6 | $5,918 |
| Novartis | 2 | $5,502 |
| Swedish Orphan Biovitrum AB | 1 | $4,250 |
| Secura Bio, Inc. | 1 | $3,750 |
| Bristol Myers Squibb | 7 | $3,211 |
| Partner Therapeutics, Inc. | 2 | $2,498 |
| Medexus Pharma, Inc. | 1 | $2,040 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,000 |
| Dr.reddy's Laboratories,inc. | 1 | $2,000 |
| GSK | 1 | $1,950 |
| Kadmon Pharmaceuticals LLC | 1 | $1,605 |
| EUSA Pharma (US) LLC | 1 | $1,500 |
| National Marrow Donor Program | 4 | $694 |
| Karyopharm Therapeutics Inc. | 3 | $300 |
| Sanofi | 1 | $103 |
| Autolus Inc | 1 | $38 |
| Johnson & Johnson | 1 | $38 |
| Grifols Shared Services North America, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$321,061 in reported general payments places this provider in the 95th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ursodiol | 19 | $2,238 |
| Acyclovir | 95 | $1,905 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 57 | $360 |
| Pantoprazole Sodium | 20 | $249 |
| Prednisone | 21 | $132 |
| Rosuvastatin Calcium | 11 | $98 |
| Allopurinol | 11 | $90 |
| Lisinopril | 14 | $38 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in New York
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Ross LevineNew York$968K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
- Jeffrey LaurenceNew York$640K
- John AllanNew York$580K
- Ilan ShapiraNew York$475K
- John MascarenhasNew York$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.